Research programme: skin disorder therapeutics - Sirona Biochem

Drug Profile

Research programme: skin disorder therapeutics - Sirona Biochem

Alternative Names: KEL-01

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirona Biochem
  • Class Glycopeptides
  • Mechanism of Action Collagen modulators; Gene expression modulators; NF-E2-related factor 2 modulators; Protein synthesis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne vulgaris; Keloids

Highest Development Phases

  • Preclinical Keloids
  • Research Acne vulgaris

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics data from the preclinical trials in keloids released by Sirona Biochem
  • 16 May 2016 Early research in Acne vulgaris in Canada (unspecified route)
  • 16 May 2016 Preclinical trials in Keloids in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top